PMID- 31336574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 7
IP  - 3
DP  - 2019 Jul 22
TI  - Reduction in Use of Risperidone for Dementia in Australia Following Changed 
      Guidelines.
LID - 10.3390/pharmacy7030100 [doi]
LID - 100
AB  - Background: Risperidone is the only antipsychotic approved in Australia for the 
      management of the behavioural and psychological symptoms of dementia (BPSD). In 
      June 2015, the Australian Government Therapeutic Goods Administration (TGA) 
      amended the indication to restrict use in BPSD to patients with Alzheimer's 
      dementia for a maximum twelve-week duration. We aimed to determine whether the 
      rate and duration of risperidone use for BPSD decreased following the regulatory 
      changes. Methods: we conducted a study using the Australian Government Department 
      of Veterans' Affairs administrative claims data and Pharmaceutical Benefits 
      Scheme (PBS) 10% sample data. We included people aged 65 years or older and 
      compared the rate and duration of risperidone use before and after the TGA 
      labelling changes. Results: There was a sustained decrease in the trend of 
      risperidone use for BPSD following the TGA labelling changes, with a monthly 
      decrease of 1.7% in the aged care population, 0.5% in the community living 
      population and 1.5% in the general older Australian population. Overall, in the 
      24 months post the TGA changes the reduction in the rate of use of risperidone 
      ranged from 20% to 28% lower than compared to what the rate would have been 
      without the TGA changes. The median duration of use of risperidone in aged-care 
      residents decreased from 338 days in the year prior to the TGA labelling changes, 
      to 240 days per person in the year after the changes. Conclusion: The TGA 
      labelling changes were associated with a significant reduction in the rate of use 
      of risperidone for BPSD in veterans living in both the aged care and community 
      settings, and in the general older Australian population. The labelling changes 
      were also associated with a reduced duration of risperidone use in aged care 
      residents, although for most people the duration of use still exceeded the 
      recommended 12-week maximum duration.
FAU - Kalisch Ellett, Lisa M
AU  - Kalisch Ellett LM
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and 
      Medical Sciences, University of South Australia, GPO Box 2471, Adelaide SA 5001, 
      Australia. lisa.kalisch@unisa.edu.au.
FAU - Moffat, Anna K
AU  - Moffat AK
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and 
      Medical Sciences, University of South Australia, GPO Box 2471, Adelaide SA 5001, 
      Australia.
FAU - Gadzhanova, Svetla
AU  - Gadzhanova S
AUID- ORCID: 0000-0002-7493-7387
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and 
      Medical Sciences, University of South Australia, GPO Box 2471, Adelaide SA 5001, 
      Australia.
FAU - Pratt, Nicole L
AU  - Pratt NL
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and 
      Medical Sciences, University of South Australia, GPO Box 2471, Adelaide SA 5001, 
      Australia.
FAU - Apajee, Jemisha
AU  - Apajee J
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and 
      Medical Sciences, University of South Australia, GPO Box 2471, Adelaide SA 5001, 
      Australia.
FAU - Woodward, Michael
AU  - Woodward M
AD  - Austin Health, GPO Box 5444, Heidelberg West, Victoria 3081, Australia.
FAU - Roughead, Elizabeth E
AU  - Roughead EE
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and 
      Medical Sciences, University of South Australia, GPO Box 2471, Adelaide SA 5001, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20190722
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC6789876
OTO - NOTNLM
OT  - antipsychotics
OT  - behavioural and psychological symptoms of dementia (BPSD)
OT  - medication use restrictions
OT  - older people
OT  - potentially inappropriate medicines
OT  - risperidone
COIS- The authors declare no conflict of interest.
EDAT- 2019/07/25 06:00
MHDA- 2019/07/25 06:01
PMCR- 2019/07/22
CRDT- 2019/07/25 06:00
PHST- 2019/06/11 00:00 [received]
PHST- 2019/07/01 00:00 [revised]
PHST- 2019/07/15 00:00 [accepted]
PHST- 2019/07/25 06:00 [entrez]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2019/07/25 06:01 [medline]
PHST- 2019/07/22 00:00 [pmc-release]
AID - pharmacy7030100 [pii]
AID - pharmacy-07-00100 [pii]
AID - 10.3390/pharmacy7030100 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2019 Jul 22;7(3):100. doi: 10.3390/pharmacy7030100.